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The phosphatidylinositol-3,4,5-triphosphate (PIP3) binding func-
tion of pleckstrin homology (PH) domain is essential for the acti-
vation of oncogenic Akt/PKB kinase. Following the PIP3-mediated
activation at the membrane, the activated Akt is subjected to other
regulatory events, including ubiquitination-mediated deactivation.
Here,by identifyingand characterizing an allosteric inhibitor, SC66,
we show that the facilitated ubiquitination effectively terminates
Akt signaling. Mechanistically, SC66 manifests a dual inhibitory ac-
tivity that directly interferes with the PH domain binding to PIP3
and facilitates Akt ubiquitination. A known PH domain-dependent
allosteric inhibitor, which stabilizes Akt, prevents the SC66-induced
Akt ubiquitination. A cancer-relevant Akt1 (e17k) mutant is unsta-
ble, making it intrinsically sensitive to functional inhibition by SC66
in cellular contexts in which the PI3K inhibition has little inhibitory
effect. As a result of its dual inhibitory activity, SC66 manifests
a more effective growth suppression of transformed cells that con-
tain a high level of Akt signaling, comparedwith other inhibitors of
PIP3/Akt pathway. Finally, we show the anticancer activity of SC66
by using a soft agar assay as well as a mouse xenograft tumor
model. In conclusion, in this study, we not only identify a dual-
function Akt inhibitor, but also demonstrate that Akt ubiquitina-
tion could be chemically exploited to effectively facilitate its
deactivation, thus identifying an avenue for pharmacological inter-
vention in Akt signaling.
chemical screening | cell death
A
number of pathogenic conditions, including cancer, arise
from perturbation of intracellular signaling pathways that
control the amount of phosphatidylinositol-3,4,5-triphosphate
(PIP3)atthe membrane.PIP3level ismainly controlled positively
by PI3K and negatively by lipid phosphatase PTEN (1, 2). PIP3
exerts its functions by mediating the recruitment of various sig-
naling effectors at the membrane. The serine/threonine protein
kinase Akt (also known as PKB) is one of the major downstream
effectors recruited by PIP3.Akt contains an N-terminal pleckstrin
homology (PH) domain, which speciﬁcally binds to PIP3, en-
abling its membrane translocation and subsequent activation by
upstream kinases (3,4). The activated Akt, in turn, phosphor-
ylates a variety of proteins involved in diverse cellular processes,
including cell proliferation and survival (5).
Because of its crucial involvement in tumorigenesis and drug
resistance of cancer cells, the PIP3/Akt pathway has been the
primary target for anticancer drug development (5, 6). Various
current efforts to inhibit Akt function are mainly focused in two
aspects: reducing PIP3 level and inhibiting Akt activity (7–11).
We also showed that two inositol phosphates, InsP7 and Ins
(1,3,4,5)P4,competewithPIP3forbindingtoAktPHdomain(12,
13). Additionally, recent studies revealed that the ubiquitination
of Akt plays important regulatory functions (14–16), providing
a potential new avenue for pharmacological intervention. In this
study, we identiﬁed and characterized a dual-function Akt in-
hibitor that directly facilitates Akt ubiquitination and deacti-
vation. We demonstrated its efﬁcacy toward a cancer-relevant
and PI3K inhibitor-resistant Akt1 (e17k) mutant. As a result of its
dual inhibitory activity, SC66 manifests a more effective growth
suppression of transformed cells compared with other inhibitors
of PIP3/Akt pathway. Therefore, this study offers validation for
the chemical-assisted ubiquitination as a legitimate strategy to
terminate Akt signaling.
Results
Cell-Based Screening Identiﬁes a Compound that Directly Facilitates
Akt Ubiquitination. To better understand the regulatory mecha-
nisms of the PIP3/Akt pathway, we carried out an image-based
chemical screening by using the spatial distribution of Akt1 PH
domain/EGFP fusion protein (PH-EGFP) as a read-out (to be
described elsewhere). This screening identiﬁed a group of 12
chemicals (termed group II) that not only prevented the mem-
brane translocation of PH-EGFP, but also induced its accumula-
tion into a subcelluar location reminiscent to the pericentrosomal
region (Fig. S1 and Dataset S1). Interestingly, the compounds
SC13, SC66, and SC67 contain a pyridine moiety that is also found
in some chemicals known to inhibit Akt (17, 18). In this study, we
focusedoncharacterizingSC66asa representativeofthisgroupof
compounds. First, we conﬁrmed that this subcellular location in-
deed represented the pericentrosomal region by immunostaining
withγ-tubulin,a centrosomalmarker(Fig.1A).TheSC66-induced
pericentrosomal accumulation was speciﬁcally mediated by Akt
PH domain, as EGFP alone or EGFP fused to PH domain from
PLC-δ had no effect (Fig. 1A). Other group II compounds also
showed no effect on the membrane localization of PH-PLCδ-
EGFP (Fig. S2). The level of PIP3 at the membrane did not affect
the SC66-induced pericentrosomal localization, as cotreatment
with IGF1 or PI3K inhibitor failed to yield any differential effects.
Likewise, a PIP3-nonbinding mutant PH (r25c)–EGFP was also
accumulated in the pericentrosomal region. As revealed by co-
localization with PH-EGFP, the full-length Akt1 could be also
accumulatedin this regionby SC66 and othergroup IIcompounds
(Fig. 1A and Fig. S3). To test if SC66 could inhibit the Akt sig-
naling pathway, HEK293T cells, which were shown to contain
a high level of PIP3 (19), were treated with different amounts of
SC66, and the whole-cell lysates were examined for the phos-
phorylation level of Akt and its known target proteins (Fig. 1B).
At a concentration that led to the pericentrosomal accumulation,
SC66 signiﬁcantly reduced the phosphorylation level of both Akt
and its targets, but not those of other cellular kinases. Impor-
tantly, unlike the Akt phosphorylation at S473, the phosphoryla-
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not manifest inhibitory effects toward upstream kinase mTorc2,
which was reported to be responsible for the phosphorylation of
bothT450andS473ofAkt.Wealsotestedtheinhibitoryeffectsof
SC66 and other group II compounds on the Akt activation stim-
ulated by IGF1 in HeLa cells. (Fig. S4A). Overall, all these
chemicals inhibited Akt phosphorylation at or below the con-
centration of 8 μg/mL, which is equivalent to 1× concentration of
the initial high-throughput chemical screening. The cytoplasm to
nuclear translocation of proapoptotic transcription factor Foxo1
istightlyregulated byAkt activity. Toassesstheeffects ofgroupII
compounds on Akt function at the cellular level, we used live cell
imaging by using EGFP-Foxo as a read-out (20). The majority of
group II compounds were found to inhibit the cytoplasmic re-
tention of EGFP-Foxo, whereas SC67, 86, and E26 displayed
relatively weaker inhibitory activity (Fig. S4B). To determine if
the group II compounds could also affect the levels of PIP3, the
selected compounds were treated to serum-starved HeLa cells.
Following IGF1 stimulation, the level of PIP3 was measured (Fig.
S4C). Unlike the PI3K inhibitor LY294002, none of the tested
group II compounds signiﬁcantly reduced the PIP3 level, in-
dicating that their inhibitory effect on the Akt phosphorylation
was not caused by reduction of PIP3 level. This ﬁnding was also
consistentwiththeirinhibitorypatternsoftargetphosphorylation,
more similar to Akt inhibition than PI3K inhibition (Fig. S4A).
Next,wesoughttodeterminethemechanismsofgroupII-mediated
inhibition of Akt activation. As these compounds did not affect the
cellularPIP3level,weexploredthepossibilitythattheymaydirectly
interferewith the PIP3binding function ofPH domain. Totest this
idea, puriﬁed PH-EGFP was incubated with PIP3-coated beads
in the presence of group II compounds. The amount of PH-EGFP
broughtdownbythePIP3-beadswouldbeinverselycorrelatedwith
the inhibitory activity of compound toward the PIP3 binding
function of PH domain (Fig. S4D). This assay implicated that all
group II compounds, in varying degrees, could interfere with PH
domain binding to PIP3 in vitro.
One of the important functions of the pericentrosomal region
is the recycling and degradation of cellular proteins (21). The
accumulation of Akt in this region may reﬂect its degradation
through the ubiquitin-mediated proteasomal pathway. Indeed,
when HEK293 cells stably expressing Akt1, HEK293-Akt1, were
treated with SC66, a robust accumulation of the ubiquitinated
Akt was observed (Fig. 1C). The level of SC66-induced Akt
ubiquitination was further increased by cotreatment with the
proteasome inhibitor MG132. A similar result was also observed
with the endogenous Akt in HeLa cells (Fig. S5A). A longer
treatment of SC66 decreased the level of total Akt in both HeLa
and HEK293T cells (Fig. S5B). Together, these results con-
ﬁrmed that the ubiquitinated Akt by SC66 could be targeted for
proteasome-mediated degradation. Some group II compounds
also led to the accumulation of ubiquitinated Akt (Fig. S5C). Of
note is the ﬁnding that SC67, which is structurally similar to
SC66 (Fig. S1), led to a much weaker accumulation of ubiq-
uitinated Akt. All group II compounds, including SC66, did
not display any signiﬁcant inhibitory effects toward the cellular
proteasome or deconjugation (i.e., deubiquitination) activity
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Fig. 1. Cell-based screening identiﬁes a compound that directly facilitates Akt ubiquitination. (A) HeLa-PH-EGFP cells were treated with SC66 (4 μg/mL) for
1 h and were stained with the γ-tubulin antibody (red). Arrows indicate the colocalization of PH-EGFP with γ-tubulin (Left). HEK293 cells transfected with the
indicated EGFP fusion proteins were treated with SC66 alone or together with IGF1 (20 ng/mL) or wortmannin (200 nM). After 1 h, pericentrosomal local-
ization was visualized in live cells. Arrows indicate the pericentrosomal region (Middle). HEK293 cells stably expressing PH-EGFP were transfected with the
C-terminal V5/His tagged Akt1. Following treatment with SC66 for 1 h, the ﬁxed cells were stained for Akt1. Colocalization with PH-EGFP in pericentrosomal
region is indicated by arrows (Right). (B) HEK293T cells grown in serum-rich medium were treated with different amounts of SC66 for 1 h. The whole-cell
lysates were analyzed with the indicated antibodies. (C) HEK293-Akt1 cells were treated with SC66 (4 μg/mL), MG132 (10 μg/mL), or a combination of the two
for 4 h, and the whole-cell lysates were analyzed by a monoclonal V5 antibody (Upper). The cell lysates from SC66-treated cells were supplemented with 50
mM imidazole followed by incubation with Ni-NTA beads in the presence or absence of 1 mM DTT. The bead-bound fraction was resolved on a SDS/PAGE and
blotted with the V5 antibody for Akt1. The same membrane was autoclaved and sequentially blotted with a rabbit polyclonal antibody against ubiquitin
(Lower). (D) HEK293 cell lysates were subjected to in vitro ubiquitination assay with or without SC66 for different times (Left). The Akt1 immune complex was
treated with DMSO or SC66 for 1 h, and washed three times with the buffer. The resulting immune complex was subjected to in vitro ubiquitination with fresh
HEK cell lysates (Right). (E) Inhibitory effect of an allosteric Akt inhibitor, AKTi-VIII, on the SC66-induced in vitro ubiquitination of Akt1.
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group II compounds could directly affect Akt ubiquitination
(Fig. S6A). The in vitro ubiquitination of Akt using the control
HEK293 cell extracts appeared inefﬁcient, and only a weak level
of ubiqutinated Akt could be observed. Strikingly, however, in
the presence of SC66 in this cell-free system, a robust ubiquiti-
nation was observed (Fig. 1D). The enhanced in vitro ubiquiti-
nation of Akt by SC66 was both time- and dose-dependent (Fig.
1D and Fig. S6B). Compared with the other group II compounds
in the same in vitro assay, SC66 displayed the strongest activity,
followed by SC67 and SC11 (Fig. S6C).
To further test if the drug-bound Akt was susceptible for ubiq-
uitination, the Akt immune complex was incubated with SC66.
Afterremovalofthecompoundbyextensivewashing,theresulting
immune complex was subject to in vitro ubiquitination in the
presence of fresh cell lysates (Fig. 1D). Intriguingly, the pre-
treatment of drug alone was found to be sufﬁcient, indicating that
the drug-bound Akt was amenable (or primed) for the subse-
quent ubiquitination.
The efﬁciency of ubiquitination could be dependent upon the
conformation(s) of target protein. To test if this is the case for
the SC66-induced Akt ubiquitination, we took advantage of a
known PH domain-dependent allosteric Akt inhibitor, AKTi-
VIII (22), and asked if the SC66-induced Akt ubiquitination
could be affected by this inhibitor. Surprisingly, when the lysates
were preincubated with AKTi-VIII, the subsequent ubiquitina-
tion by SC66 was almost completely abolished (Fig. 1E). When
SC66 was added ﬁrst, followed by AKTi-VIII, Akt ubiquitination
was also affected, but to a lesser extent. Other chemicals known
to inhibit Akt functions failed to show any inhibitory effects (Fig.
S6D). Together, these results conﬁrm that SC66 directly facili-
tates Akt ubiquitination.
SC66 Functionally Inhibits a Cancer-Relevant Akt1 (e17k) Mutant. A
gain-of-function mutation in PH domain (e17k) of Akt1 has been
identiﬁed from human cancers (23). Next, we examined if SC66
could be effective in functional inhibition of this mutant Akt1. As
previously reported, when expressed in HEK293 cells, compared
with the WT, the level of phosphorylated Akt was much higher in
Akt1 (e17k), and a strong enrichment of phosphorylated Akt was
found at the plasma membrane (Fig. S7A). We examined if group
II compounds could inhibit the activation of this mutant. Seven
group II compounds (SC1, 13, 19, 23, 27, 63, and 66) led to
a greater than 50% inhibition in comparison with DMSO control
(Fig. S7B). Intriguingly, SC66 manifested the strongest inhibitory
activity, whereas its structural analogue, SC67, showed a marginal
effect. To obtain a structure–activity relationship, we further
conﬁrmed the dose-dependent inhibitory effects of these two
compounds on the activation of Akt1 (e17k) (Fig. 2A). This result
was consistent with their relative activity to induce Akt ubiquiti-
nation (Figs. S5C and (S6C). To test if SC66 could inhibit the
membranelocalizationofthismutantPHdomain,thePH(e17k)–
EGFP was expressed in HeLa cells and live cell imaging was
performed. The membrane localization of PH (e17k)–EGFP was
insensitive to inhibition of PI3K, as previously reported (23).
However, SC66 effectively prevented its membrane localization
whereas SC67 showed little inhibitory effect (Fig. 2B). When
similar experiments were done with the WT PH-EGFP, both
compounds effectively preventedthemembranelocalization (Fig.
S8). Intriguingly, however, the pericentrosomal localization was
moreprominentinthepresenceofSC66.Thisresultappearstobe
consistent with their relative activity in inducing Akt ubiquitina-
tion. Both SC66 and SC67 contained the pyridine moiety, and
some Akt inhibitors were also shown to have this moiety (17, 18).
Therefore, we also tested other pyridine-containing compounds
represented in the screening library. At the comparable amount,
none of these other compounds showed any inhibitory effect
(Fig. 2B).
Next, we examined if Akt1 (e17k) could be also ubiquitinated
by SC66. Compared with WT, Akt1 (e17k) displayed a slightly
faster kinetics of ubiquitination, and the phosphorylated (S473)
Akt could be also ubiquitinated in this in vitro reaction. It has
been shown that phosphorylation at turn motif (T450) by mTorc2
complex regulates Akt maturation and stability (24, 25). How-
ever, Akt1 (e17k) showed a comparable level of phosphorylation
at T450 as the WT (Fig. S9A). Nonetheless, compared with the
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Fig. 2. SC66 functionally inhibits a cancer-relevant Akt1 (e17k) mutant. (A) HEK293 cells stably expressing Akt1 (e17k) mutant were treated with different
amounts (2, 4, 8 μg/mL) of SC66 or SC67 for 1 h, followed by Western blot for phospho-Akt (S473). (B) HeLa cells expressing PH (e17k)–EGFP were treated with
LY294002 (40 μM) or indicated compounds (4 μg/mL) in the presence of IGF1. The relative intensity of membrane PH (e17k)–EGFP between time 0 and 60 min
was quantiﬁed. The arrows indicate the pericentrosomal accumulation of PH(e17k)–EGFP. (C) HEK293-Akt1 (e17k) cells were pretreated with LY294002 or
AKTi-VIII for 30 min followed by SC66 treatment for an additional 2 h, and the cytosolic extracts were analyzed for phospho-Akt and ubiquitinated Akt1
(e17k) (Left). HeLa cells transfected with Akt1 (e17k) were treated with AKTi-VIII, SC66, or a combination of the two for 2 h. The representative immu-
nostaining for Akt1 (e17k) is shown (Right). (D) HeLa cells cotransfected with EGFP-Foxo and Akt1 (e17k) were treated with different amounts of LY294002,
SC66, or a combination of the two. The coexpressing cells were identiﬁed by immunostaining for Akt1 (e17k). The relative intensity of cytosolic versus nuclear
EGFP-Foxo was determined and scored as cytosolic (>1.1), equal (1.1–0.9), or nuclear (<0.9; Right).
6488 | www.pnas.org/cgi/doi/10.1073/pnas.1019062108 Jo et al.WT, Akt1 (e17k) was found to be unstable in the presence of 17
AAG, an inhibitor of HSP90. The instability of Akt1 (e17k) upon
inhibition of HSP90 was not affected by cellular level of PIP3, as
neither wortmannin nor LY294002 led to a signiﬁcant difference.
However, the allosteric Akt inhibitor, AKTi-VIII, signiﬁcantly
inhibited the degradation of this mutant Akt1, indicating this
inhibitor acts as a stabilizer (Fig. S9B). Similarly, we examined
the effects of cellular PIP3 level and Akt conformation on the
SC66-induced ubiquitination. The pretreatment of AKTi-VIII,
but not LY294002, almost completely inhibited the SC66-induced
ubiquitination of Akt1 (e17k) (Fig. 2C). This differential effect
was consistent with their respective inhibitory activity toward
the SC66-induced in vitro Akt ubiquitination (Fig. 1E). To ex-
amine this effect at the cellular level, HeLa cells expressing
Akt1 (e17k) were treated with AKTi-VIII, SC66, or a combina-
tion of the two, and immunostaining was performed. In control
cells, Akt1 (e17k) was predominately at the membrane, and
nuclear localization was also evident. AKTi-VIII dramatically
perturbed this cellular localization, making it evenly distributed
throughout the cytoplasm (Fig. 2C). In the presence of SC66, the
level of membrane-associated and cytosolic Akt1 (e17k) was re-
duced, with a prominent increase in the nucleus. Importantly,
when combined, the pattern of its localization resembled that
of AKTi-VIII treatment alone (Fig. 2C).
The ﬁnding that SC66 was effective toward the Akt1 (e17k)
mutant has an important implication, as human cancers carrying
this mutation would be resistant to any therapeutic manipu-
lations to reduce the PIP3 level. Therefore, we next compared
the efﬁcacy of SC66 with LY294002 in inhibiting Akt1 (e17k)
function. When coexpressed with Akt1 (e17k), EGFP-Foxo was
predominantly localized in the cytoplasm even in the presence
of LY294002, conﬁrming the resistance of Akt1 (e17k) toward
PI3K inhibitor. However, in the presence of SC66, a signiﬁcant
portion of EGFP-Foxo was localized to the nucleus. A sub-
sequent immunostaining conﬁrmed that only those cells ex-
pressing Akt1 (e17k) were refractory to LY294002, whereas such
cells were still sensitive to SC66 (Fig. S10).
The mechanisms by which LY294002 and SC66 inhibit acti-
vation of Akt are completely different (i.e., inhibition of PIP3
production vs. PH domain binding to PIP3). Therefore, these
two drugs should enhance the inhibitory activity toward Akt1
(e17k) function when combined. To test this possibility, EGFP-
Foxo was cotransfected with Akt1 (e17k) and treated with dif-
ferent amounts of LY294002, SC66, or a combination of the two.
The localization of EGFP-Foxo in cells expressing Akt1 (e17k)
was analyzed and scored as cytosolic, equal, or nuclear to reﬂect
the strength of functional inhibition of Akt1 (e17k) (Fig. 2D).
Consistent with the previous ﬁndings, even at a high concen-
tration of LY294002, most EGFP-Foxo was localized to the cy-
toplasm. The majority of EGFP-Foxo at lower concentration of
SC66 alone was equally distributed in the cytoplasm and nucleus.
However, when combined with LY294002, the proportion of
cells containing nuclear EGFP-Foxo was substantially increased.
SC66 Enhances Cancer Cell Death Mediated by PI3K Inhibition. Pre-
viously, we established deactivation of Akt as a crucial mediator
of cancer cell death (26). Accordingly, we evaluated the phar-
macological properties of SC66 as a potential anticancer agent.
Inhibition of Akt is known to suppresses the motility of cancer
cells (27). Similar to LY294002 and AKTi-VIII, SC66 but not
SC67 effectively inhibited the migration of HeLa cells (Fig. 3A
and Fig. S11 A and B). To examine the effects on cell pro-
liferation/death, we used time-lapse imaging, which allowed us to
monitor the mitotic and apoptotic cells in a real-time fashion (28).
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Fig. 3. SC66 enhances cancer cell death mediated by PI3K inhibition. (A) Conﬂuent HeLa cells were scratched and, following a 10-min recovery, the indicated
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sentative pictures of time-lapse (14 h) live cell imaging of HeLa cells treated with LY294002, SC66, or a combination of the two. The quantiﬁcation is presented
in Fig. S13C. FACS analysis of HeLa cells treated with LY294002, SC66, or a combination of the two for 20 h. The quantiﬁcation is presented in Fig. S13D.
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number of cells entering mitosis or undergoing apoptosis during
the 14-h imaging time. In control condition, approximately 45%
of cells entered mitosis, which is consistent with a doubling time
of 20 to 24 h in HeLa cells. In the presence of different inhibitors
of PI3K, AKTi-VIII, or SC66, this percentage was reduced to
10% to 30%, conﬁrming the growth-inhibitory property of these
chemicals. Within this time period, no dramatic cell death could
be observed with all chemicals tested, including SC66 (Fig. 3B).
The relative growth inhibition was correlated with the level of
phosphorylated Akt in the presence of each compound (Fig.
S12). When treated in HeLa cells grown in serum-rich con-
ditions, SC66 effectively inhibited phosphorylation of both Akt
and its targets. Importantly, consistent with their different mode
of action in preventing Akt activation, a combined treatment of
SC66 and LY294002 led to an efﬁcient inhibition (Fig. S13A).
PIP3 is required for various cellular processes, and cancer cells
may activate the compensatory mechanisms when PI3K is
inhibited. When treated with LY294002, the level of Akt phos-
phorylation reached the lowest level within the ﬁrst 1 h, but was
recovered in the next several hours. A similar trend was also
observed with wortmannin, an irreversible PI3K inhibitor. Im-
portantly, the kinetics and degree of recovery were almost iden-
tical between two different concentrations of wortmannin (Fig.
S13B). Also, because both LY24002 and wortmannin were ef-
fective in inhibiting cell proliferation (Fig. 3B), the chemical
instability alone did not explain this effect. Similarly, when HeLa
cells were treated with LY294002, a prominent nuclear locali-
zation of EGFP-Foxo was observed within the ﬁrst 1 h. However,
after overnight treatment, most of EGFP-Foxo was localized to
the cytoplasm of surviving cells (Fig. 3C). More importantly,
when these HeLa cells were subsequently treated with the same
amount of LY294002, only approximately 50% of cells displayed
the nuclear EGFP-Foxo, indicating the activation of compensa-
tory mechanisms. In contrast, when SC66 was administered to
these cells, an efﬁcient inhibition of Akt activity was still ob-
served, conﬁrming that LY294002-resistant Akt activation could
be suppressed by SC66 (Fig. 3C). If SC66 effectively suppresses
the reactivation of Akt in cancer cells that had survived the in-
hibition of PI3K, then the combined treatment would result in an
enhanced apoptosis. We examined this effect by live cell imaging
of HeLa cells treated with SC66 (Movie S1), LY294002 (Movie
S2), or a combination of the two (Movie S3). Surprisingly, when
combined in a concentration at which neither of the two drugs
alone was effective, a dramatic cancer cell death was observed
(Fig. 3D, Fig. S13 C and D, and Movie S3). This synergistic cell
death was not restricted to epithelial cancer cells, but was also
observed in HS-Sultan cells, a lymphoma cell line (Fig. S13E).
SC66 Manifests Anticancer Activity in Vitro and in Vivo. SC66displays
a dual-inhibitory function toward Akt activity: inhibition of the
initial activation by interfering with PH domain binding to PIP3
and deactivation by facilitated ubiquitination. We reasoned that,
becauseofthisdualinhibitoryactivity,SC66maymanifesteffective
anticancer activity in cancer cells with a high level of PIP3 signal-
ing. Consistent with this prediction, compared with control, SC66
preferentiallysuppressedtheviabilityofHEKcellstransformedby
SV40 large T antigen (HEK293T) or oncogenic Ras (HEK-Ras),
both of which retained elevated Akt signaling, even in the absence
of serum growth factors (Fig. S14). In addition, at a comparable
concentration, SC66 resulted in a more effective inhibition of
phosphorylation of Akt and its target proteins compared with
LY294002 and API-2, an Akt inhibitor (29) (Fig. 4A). This bio-
chemical result wascorrelated with their relativegrowthinhibitory
effect as determined by the cell viability assay (Fig. 4B). The an-
ticancer activity of SC66 was further supported by its potent in-
hibitory effects on the colony formation of HEK293T cells grown
on soft agar (Fig. 4C). Finally,by using themouse xenograft tumor
model, we tested if this anticancer activity could be extended to in
vivo. Seven days after the inoculation of HEK293T cells, the mice
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Fig. 4. SC66 manifests anticancer activity in vitro and in
vivo.(A)HEK293Tcellsgrowninserum-richmediumwere
treated with the indicated amounts of each compound
for 1 h. The phosphorylation levels of Akt and its target
proteins were examined. (B) HEK293T cells were treated
with the indicated amounts of each compound for 16 h,
and cell viability was determined by MTT assay. (C)I n -
hibitory effect of SC66 toward colony formation of
HEK293Tcellsonsoftagar.Representativeimageofwells
following a 3-week culture in the presence of different
amounts of SC66 is shown. Quantiﬁcation is from three
independent experiments. (D) HEK293T cells were in-
oculated into the nude mice, and the mice were treated
with vehicle alone or two different concentrations of
SC66. The growth of tumors was measured at the in-
dicated time points. Representative images of dissected
tumors after 28 d are shown. P values between paired
groups (Student t test) are as follows: control vs. SC66
15 mg/kg, P = 0.0209; control vs. SC66 30 mg/kg, P =
0.0190; and SC66 15 mg/kg vs. SC66 30 mg/kg, P = 0.0121.
6490 | www.pnas.org/cgi/doi/10.1073/pnas.1019062108 Jo et al.were injected with SC66 twice per week and thesize of tumors was
measured every 3 d for 21 d. Compared with vehicle alone, SC66
led to a signiﬁcant inhibition of tumor growth, conﬁrming the an-
ticancer property in vivo (Fig. 4C).
Discussion
In this study, we identiﬁed a group of chemicals that inhibit Akt
activation through interfering with PH domain binding to PIP3,
and lead to pericentrosomal localization of Akt. Altering the
spatial distribution of Akt can lead to functional perturbation
by affecting substrate recognition and facilitating dephosphory-
lation. Elucidating the mode of action of these compounds will
undoubtedly provide important new insights into the regulatory
mechanisms of oncogenic PIP3/Akt signaling pathway and the
development of new therapeutic strategies. We extensively char-
acterized a pyridine-based allosteric Akt inhibitor, SC66, that
directly facilitates Akt ubiquitination in vitro and in vivo. We
elucidated the mechanisms of its dual inhibitory function, iden-
tiﬁed the efﬁcacy toward a cancer-relevant and PI3K inhibitor-
resistant Akt1 (e17k) mutant, and demonstrated the synergistic
apoptotic activity with the PI3K inhibitor and the in vivo anti-
cancer efﬁcacy as a single agent. We also showed that, because of
its unique dual inhibitory activity, SC66 manifested a more ef-
fective growth suppression of transformed cells compared with
other inhibitors of PIP3/Akt pathway.
The phosphorylated Akt was found to be ubiquitinated in an in
vitro assay. Intriguingly, the phosphorylated and ubiquitinated Akt
could be hardly detectable in lysates from cells treated with SC66.
Inhibition of initial phosphorylation by preventing Akt mem-
brane translocation may explain this ﬁnding. However, given its
efﬁcacy toward Akt dephosphorylation in HEK293T cells, which
contain a high level of PIP3, also indicates other possibilities. For
example, the phosphorylated Akt, when bound to SC66, might be
rapidly dephosphorylated and/or the ubiquitinated Akt by SC66
might be less likely to be phosphorylated. This prediction would
be consistent with its inhibitory effects toward Akt1 (e17k) mu-
tant, which is “membrane-prone” independent of PIP3. Further
studies, including the identiﬁcation of cellular factors involved in
SC66-mediated Akt ubiquitination, are needed to clarify these
issues. As such, SC66 represents a unique chemical tool to in-
vestigate the mechanisms of ubiquitination-dependent Akt reg-
ulation in physiological and stressed conditions.
Materials and Methods
Cell Culture and Stable Cell Lines. For routine maintenance, all cell lines were
cultured in medium supplemented with 10% FBS and 1% penicillin and
streptomycin under 5% CO2. HEK293, HeLa, and their derivative cell lines
were maintained in DMEM. NB4 and HS-Sultan cells were cultured in RPMI
medium. HeLa cell lines stably expressing PH-EGFP were described previously
(30). Other stable HEK293 cell lines expressing Akt1 mutants, Akt 3, or PH-
EGFP were generated by transfecting the corresponding expression plasmids
and selected and maintained in the presence of G418 (Invitrogen).
Time-Lapse Live Cell Imaging for Spatial Distribution of EGFP Fusion Proteins.
HeLa cells transfected with the plasmids encoding the EGFP fusion proteins
were plated into a 35-mm glass-bottom dish (MatTek) and cultured for
24 to 48 h before imaging. For PH-EGFP membrane translocation assay, cells
were serum-starved in 2 mL Leibovitz L15 medium for 1 to 2 h, which was
replacedwith 1mL offresh serum-freeLeibovitzL15mediumcontainingeach
compound. After 30 min incubation, IGF1 (5 ng/mL) was added and an image
was taken every 5 to 10 min under a 40× oil objective lens. The relative
ﬂuorescent intensity at the membrane versus adjacent cytoplasm (for PH-
EGFP) or cytoplasm versus nucleus (for EGFP-Foxo) was determined. Western
blot and immnunostaining, PIP3 ELISA, in vitro PIP3 binding, in vitro ubiq-
uitination assay, time-lapse live cell imaging analysis for mitotic and apoptotic
cells, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as-
say, and other related assays are described in SI Materials and Methods.
Mouse Xenograft Experiment. Eight-week-old female NOD/SCID mice were
used inthis study. Fifteen micereceived an s.c. injection of2 × 10
6293Tcells in
the both ﬂanks. Seven days after injection, mice were randomized into three
groups (n = 5 mice per group) to receive vehicle (control) or SC66 15 mg/kg
or 30 mg/kg i.p. SC66 dissolved in DMSO was further diluted in 0.2 mL of PBS
solution containing 25% ethanol for i.p. injections. SC66 was administered
twice per week (total of six times). The size of tumor was measured three
times per week by using a caliper, and mice were killed on day 28 after the
injection of cancer cells. The tumor volumes were calculated as length ×
width
2 × 0.52. Data are presented as the mean value. A Student t test was
performed to evaluate the difference between mean values. P < 0.05 was
considered to indicate a statistically signiﬁcant difference.
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ID Mol. Formula M. W. Conc.
a PIP3 binding
c EGFP-Foxo
e 
PLCδ-PH Inhibition of PH Nuclear  
µM at Live cell  domain binding  Foxo after
 8 µg/ml First Second 16 µg  8 µg 4 µg 8 µg to PIP3 beads  HeLa NB4 HsSultan IGF
SC1 C9NO4 191 42 + + + + + - +/- + + + ++
SC11 C18H14N2O5 338 24 + + + + + - + + + + ++
SC13 C21H17N2O3SBr 456 18 + + + + + - ++ + n.d. n.d. ++++
SC19 C14N2OCl2 282 28 + + + + + +/- +++ + + + ++
SC23 C15H14N4O3S 326 25 + + + + + - +++ + + - ++++
SC27 C10H7NOS 189 42 + + + + + - ++ + + - ++++
SC49 C18H11N3O6 365 22 + + + + + - + + + + +++
SC63 C13H12N2O2S2 292 27 + + + + + - ++ + + + +
SC66 C18H16N2O 276 29 + + + + + - +++ + + + ++
SC67 C18H17N3O 291 27 + + + + +/- - ++ + + + ++
SC86 C18 H16 N4 O2 S2 384 21 + + + + + - + + n.d. n.d. +
E26 C11H9NO3 203 39 + + + + + - ++ + + + +
Live cell imaging High throughput
Akt PH
 Membrane translocation / localiztion assay
b Western blot
d
Effect on pAkt level
drug conc. (8 µg/ml)Supporting Information
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SI Discussion
Deactivation of PIP3/Akt signaling pathway suppresses the
growth of tumors and the resistance of cancer cells to chemo-
therapeutic drugs (1–4). The signaling pathways for PIP3 pro-
duction and the mechanisms of PIP3-mediated Akt activation
are well established and broadly applicable to different cell
types. However, how the activated Akt is deactivated in speciﬁc
cellular contexts remains to be elucidated. Facilitating the de-
activation of Akt would enhance the efﬁcacy of various inhibitors
of PI3K, which prevent only the activation step. Inhibiting the
kinase activity of Akt will be an obvious choice. However, as
elegantly demonstrated in a recent study (5), paradoxically,
chemicals targeting the Akt kinase domain were shown to lead to
the “inhibitor-induced Akt activation,” raising concerns for the
long-term clinical utility of such inhibitors (5).
Akt is known to undergo dynamic conformational changes.
Controlling the structural integrity of Akt appears to serve as
another regulatory mechanism. For example, it has been reported
that mTorc2, apart from its activity as an S473 kinase, plays
important roles in maintaining the structural integrity and mat-
uration of Akt by phosphorylating at T450 in turn motif (6, 7).
Lack of phosphorylation at this site, as a result of genetic abla-
tion of mTorc2 components, results in the structural instability
of Akt, leading to an increased susceptibility to proteasome-
dependent degradation. We showed that, compared with WT,
Akt1 (e17k) was unstable upon inhibition of HSP90. However,
this instability did not appear to be caused by the lack of phos-
phorylation at T450. A recent study reported an enhanced
ubiquitination of Akt1 (e17k) mutant by TRAF6 E3 ubiquitin
ligase, which facilitates its membrane localization and activation
(8). We also found a faster kinetics of SC66-induced ubiquiti-
nation of this mutant.
How this mutation in PH domain leads to an enhanced Akt
ubiquitination is not clear. Further studies, including the iden-
tiﬁcation of cellular factors involved in SC66-induced Akt
ubiquitination, are needed. Ectopic expression of TRAF6 or
CHIP E3 ubiquitin ligases known to be involved in Akt ubiq-
uitination (8, 9), failed to affect the SC66-induced Akt ubiq-
uitination. Also, as SC66 inhibits Akt phosphorylation, the drug-
bound Akt is unlikely to be directly ubiquitinated by TTC E3
ubiquitin ligase, which was shown to speciﬁcally bind to and
ubiquitinate the phosphorylated Akt (10).
A wide variety of PI3K inhibitors have been developed and are
continuously being identiﬁed. One caveat of suppressing PIP3
signalingincancercellsbyPI3Kinhibitoraloneistheactivationof
compensatorymechanisms,asdemonstratedinHeLacellstreated
withLY294002orwortmannin.Likewise,targetingtheAktactivity
alone can be compensated by other AGC family member kinases.
Considering the heterogeneity and various genetic lesions of
cancers, the effective termination of Akt signaling requires
a multifaceted strategy that prevents the membrane translocation
and facilitates its deactivation. The dual-function allosteric in-
hibitor elucidated in this study exempliﬁes one such new strategy.
SI Materials and Methods
Reagents and Antibodies. Plasmids encoding human Akt1 were
initially obtained from Dana–Farber/Harvard Cancer Center
DNA Resource Core and subcloned into the pcDNA3.1/V5-His-
TOPO vector. The site-directed mutagenesis was done with the
QuikChange mutagenesis kit (Stratagene). EGFP-Foxo1 was
obtained from Addgene. All Akt- and phosphorylation-speciﬁc
antibodies were purchased from Cell Signaling Technology; V5
antibody was from Invitrogen; ubiquitin antibody (sc-9133) was
from Santa Cruz Biotechnology. All other reagents, including the
HRP-conjugated secondary antibodies, for Western blot were
from GE Healthcare. LY294002, Akt inhibitors, rapamycin, and
wortmannin were purchased from EMD Biosciences; PI-103,
PIP3-coated beads, and PIP3 ELISA kit were from Echelon.
Western Blot and Immunostaining. Preparation of cell lysates, SDS/
PAGE, and Western blot, and other standard molecular bi-
ological techniques, were essentially the same as described pre-
viously (11). For immunostaining of Akt1 (1:2,000 for V5
antibody) and phospho-Akt (1:200 for pS473), cells were ﬁxed in
3% paraformaldehyde, and followed the same procedure as
previously described (12).
PIP3 ELISA and in Vitro PIP3 Binding Assay with Puriﬁed PH-EGFP
Protein. The serum-starved HeLa cells (1 × 10
7) were pre-
treated with LY294002 (20 μM) or group II chemicals (4 μg/mL)
for 30 min, then stimulated with IGF1 (5 ng/mL) for 20 min.
Extraction of PIP3 by sequential centrifugation in methanol:
chloroform:HCl buffer and measurement of the extracted PIP3
was done using the PIP3 Mass ELISA Kit (K-2500s; Echelon),
according to the instructions. For puriﬁcation of PH-EGFP
protein, HEK cells (1 × 10
8) stably expressing PH-EGFP tagged
with the C-terminal V5/His were suspended in PBS solution
containing 0.3% CHAPS, 20 mM imidazole, and protease in-
hibitor mixtures. The cell suspension was frozen on dry ice for 30
min and thawed at room temperature. The lysates were cleared
by centrifugation and loaded on the column packed with Ni-
NTA beads (Qiagen). After washing three times in PBS solution
containing 0.3% CHAPS and 50 mM imidazole, the bound
fraction was eluted with 100 mM imidazole. The eluted protein
was concentrated in the binding buffer (10 mM Hepes, pH 7.4,
0.25% Nonidet P-40, 150 mM NaCl, 0.5 mM β-mercaptoethanol)
by centrifugation (Amicon Ultra 10K cutoff ﬁlter; Millipore).
The puriﬁed PH-EGFP protein (800 ng/mL) was preincubated
with group II compounds (1 μg/mL) for 20 min on ice, and in-
cubated with 20 μL of PIP3-coated beads (Echelon) for over-
night at 4 °C. After washing the beads three times with binding
buffer at room temperature, the amount of bead-bound PH-
EGFP protein was determined by Western blot.
Proteasome, Deconjugation, and in Vitro Ubiquitination Assay Using
Cell Lysates.HEK293 cells (1 × 10
6) were treated with compounds
(4 μg/mL) for 1 h. After washing with PBS solution, the cell
pellet was lysed on ice for 15 min in 200 μL lysis buffer (20 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
1m Mβ-glycerophosphate, 1% Triton X-100). After clearing cell
debris by centrifugation at 4 °C, the extract (50 μL) was subjected
to proteasomal activity using Proteasome-Glo Chymotrypsin-
Like Assay (G8621; Promega). The same extract was also as-
sayed for deconjugation activity by using DUB-Glo Protease
Assay (G6260; Promega). For in vitro ubiquitination assay,
HEK293 expressing Akt1 tagged with V5/HIS were lysed in
a buffer containing 50 mM Hepes, pH 7.4, 0.2% Nonidet P-40,
0.5 mM β-mercaptoethanol, and protease inhibitor mixtures. The
lysates were frozen on dry ice for 30 min and thawed at room
temperature. After centrifugation, the extract was subjected to in
vitro ubiquitination reaction. Typically, 100 to 200 μg of total
proteins were mixed with 1 μg of chemicals on ice for 10 min, and
supplemented with MG132 (5 μM), ubiquitin aldehyde (4 μM),
and ATP (5 mM) in 50 μL of ubiquitin conjugation reaction
Jo et al. www.pnas.org/cgi/content/short/1019062108 1o f1 2buffer (Boston Biochem), and incubated for 1 h followed by
Western blot.
Time-Lapse Live Cell Imaging Analysis for Mitotic and Apoptotic Cells.
HeLa cells growing exponentially (or approximately 65%–70%
conﬂuence) in 35 mm dish were replaced with 2 mL of Leibovitz
L15 medium supplemented with 10% FBS and cultured for 2 h,
and then compounds were added. The time-lapse movie was
taken every 15 min for 14 to 16 h. Each movie frame in the 14-h
time period was analyzed for mitotic or apoptotic cells as pre-
viously described (12). The mitotic cells were identiﬁed as they
underwent morphological changes from ﬂat to round shape and
cell division in later frames, and the apoptotic cells were
identiﬁed as their membrane collapsed and lost adhesion to
the plate.
MTT Assay. HEK293T cells (2.5 × 10
5) were plated in a 24-well
plate in 500 μL of phenol red-free medium supplemented with
10% FBS. The next day, different amounts of each compound
were added and cultured overnight (16–20 h), and 50 μL of MTT
solution (5 mg/mL) were added to each well and incubated for
2 h. After directly adding 500 μL of isopropanol with 0.1 M HCl
to each well to dissolve the crystals, the absorbance was mea-
sured at a wavelength of 570 nm.
Soft-AgarColonyFormationAssay.A0.6%agargelwith10%FBSin
DMEM was prepared and added to a six-well culture dish as
a base agar. HEK293T cells (3,000 per well) were plated in 0.3%
agar gel with 10% FBS in DMEM supplemented with different
concentrations of SC66 on top of the base agar and allowed to
growfor3wk.ColonieswerestainedwithCrystalvioletdye.There-
sults represent the averages from three independent experiments.
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compounds (4 μg/mL) for 1 h, the ﬁxed cells were stained for Akt1. Colocalization with PH-EGFP in pericentrosomal region is indicated by arrows.
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Fig. S4. (A) Serum-starved HeLa cells were treated with the known inhibitors of PI3K (LY294002 and PI-103), Akt (AKTi-VIII), mTorc1 (rapamycin), or three
different concentrations (2, 4, or 8 μg/mL) of group II compounds for 30 min and stimulated with IGF (5 ng/mL) for an additional 30 min. The cell lysates were
analyzed for the level of Akt phosphorylation at S473. The same blot was also probed for phosphorylation of the indicated target proteins. (B) HeLa cells
transfected with EGFP-Foxo were serum-starved and treated with group II compounds for 30 min (4 μg/mL). Following addition of IGF1 (5 ng/mL), a live cell
image was taken every 5 min. Representative image at 20 min IGF1 stimulation in the presence of each compound is shown. The intensity of cytoplasm and
nuclear EGFP-Foxo was quantiﬁed, and the relative ratio is presented (Bottom;* P < 0.05, Student t test). (C) Serum-starved HeLa cells were treated with DMSO,
LY294002 (20 mM), or the indicated group II compounds (4 μg/mL) for 30 min, followed by IGF1 (5 ng/mL) stimulation for 20 min. The amount of cellular PIP3
was measured by ELISA and calculated in reference to the standard PIP3 lipid. (D) The puriﬁed PH-EGFP protein (800 ng/mL) was preincubated with group II
compounds (1 μg/mL) for 20 min on ice followed by incubation with the PIP3-coated beads overnight in a cold room. After washing, the bead-bound fraction
was resolved on SDS/PAGE and blotted with the V5 antibody. Representative blot is shown, and the quantiﬁcation is the average of three independent
experiments.
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Fig. S5. (A) HeLa cells were pretreated with MG132 (10 μg/mL) for 2 h before addition of SC66 (4 μg/mL). Following an additional 2-h incubation, the total cell
extract, cytosolic, nuclear, or pellet (insoluble) fraction were analyzed for Akt. The same fractions were simultaneously blotted for other cellular proteins:
β-tubulin for cytosolic and PARP for nuclear fractions, respectively. (B) HeLa or HEK293T cells were treated with different amounts of SC66 for the indicated
time points and the levels of pAkt, Akt, and actin were analyzed. (C) HEK293 cells stably expressing Akt1, HEK293-Akt1, were treated with group II compounds
(4 μg/mL) for 1 h or MG132 (10 μg/mL) for 4 h, and the cell lysates were analyzed for Akt1 by Western blot with a monoclonal V5 antibody. (D) Proteasomal and
deconjugation activity from the cytosolic cell lysates were measured. Relative activity in reference to DMSO-treated cells is presented.
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Fig. S6. (A) SC66-induced in vitro ubiquitination assay for Akt. HEK293-Akt1 cell lysates were incubated with the indicated combinations of ATP, ubiquitin
aldehyde, MG132, DTT, and SC66 for 1 h. The absence of ubiquitin aldehyde, which inhibits deubiquitination, most signiﬁcantly affected the Akt ubiquiti-
nation. The ubiquitinated Akt detected in the absence of additional ATP could be a result of residual ATP and preformed E1– and E2–ubiqutin complex present
in the cell extract. In the presence of DTT, which disrupts the thioester bond between E1– and E2–ubiquitin that is required for the subsequent ubiquitination
by E3 ligases, the SC66-induced Akt ubiquitination was almost completely abolished. (B) SC66 dose-dependent in vitro ubiquitination of Akt. (C) The effect of
group II compounds on the in vitro ubiquitination of Akt1. (D) The effects of AKTi-VIII and other chemicals known to inhibit Akt pathway on in vitro ubiq-
uitination of Akt1 by SC66. The indicated amounts of chemicals were pre- or simultaneously incubated with SC66, followed by in vitro ubiquitination reaction.
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Fig. S12. Effects of long-term treatment with chemicals, as in Fig. 3B, on the levels of phosphorylated Akt in HeLa cells.
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Fig. S13. (A) HeLa cells grown in serum-rich medium were treated with LY294002, SC66, or a combination of the two for the indicated time periods, and the
cell lysates were analyzed for phosphorylation of Akt, Tsc, Foxo, and Gsk3. (B) HeLa cells were treated with LY294002 or wortmannin for the indicated time
points, and the cell lysates were analyzed for phosphorylation of Akt and its targets. (C) The quantiﬁcation of HeLa cell death determined by the live
cell imaging in Fig. 3D. The percentage of dying cells in 14 h is presented. (D) The quantiﬁcation of FACS analysis of HeLa cells treated with drugs in Fig. 3D.
*P < 0.05 by Student t test. (E) The FACS analysis of HS-Sultan cells treated with LY294002, SC66, or in combination for 20 h (*P < 0.05, Student t test).
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Fig. S14. (A) Morphology of the parental HEK293 cells and cells transformed by SV40 large T antigen (HEK293T) or H-Ras oncogene (HEK-Ras). (B) The level of
phosphorylated Akt in cells grown in serum-rich or serum-free (for 1 h starvation) medium. (C) Differential growth-suppressive effects of SC66 on parental HEK
cells and transformed cells. The relative viability was determined after 24 h treatment with SC66.
Movie S1. Live cell imaging of HeLa cells treated with SC66 (2 μg/mL). Frames were taken every 15 min for 14 h.
Movie S1
Movie S2. Live cell imaging of HeLa cells treated with LY294002 (20 μM). Frames were taken every 15 min for 14 h.
Movie S2
Jo et al. www.pnas.org/cgi/content/short/1019062108 11 of 12Movie S3. Live cell imaging of HeLa cells treated with SC66 and LY294002. Frame were taken every 15 min for 14 h.
Movie S3
Dataset S1. Characterization of group II compounds
Dataset S1 (XLS)
a8 μg/mL is the equivalent to 1× concentration of the initial high-throughput screening.
bPlus signs indicate inhibition of membrane translocation greater than 50% of control.
cNumber of plus signs represents the relative inhibitory activity compared with DMSO control.
dPlus signs indicate inhibition of Akt phosphorylation (s473) greater than 50% of control.
eNumber of plus signs represents the relative intensity of nuclear EGFP-Foxo over cytoplasm.
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